November 5-9, 2025 – SITC 2025 – Annual Meeting & 40th anniversary | National Harbor, MD
November 19-21, 2025- SFGM-TC 2025 – 24th Annual Conference | Geneva, Switzerland
November 25, 2025 – Investir Day – 7th edition | Paris, France
Exclusive License Agreement with Clinigen – Company Call July 2025
ARES Phase 3 Results Company Call Presentation
2021 – Financial Annual Report – Only in French
*Indicative calendar could be subject to change.
Preparatory Documents
Preparatory documents
Statutory Auditors Reports – (Documents in French Only)
“Patients are our priority. MaaT Pharma aims to become the source of Microbiome excellence providing patients with safe and innovative medicines. The Company develops products from sustainable biological matters, driving optimal impact of Microbiome.
We are committed to our patients and to the protection of human health by respecting environmental protection, respecting our employees, and ensuring good governance practices. Our way of working every day is driven by the 4 guidelines below :
– Innovate and raise awareness to deliver better care,
– Contribute to employees-growth within a people-oriented ecosystem,
– Place ethics and transparency at the core of the Company’s strategy,
– Control and measure our impact on the environment.
We, MaaTiens, are committed to this approach.”
Hervé Affagard, CEO of MaaT Pharma
We are a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma has reached a major milestone in its development in January 2025, with positive topline results from its Phase 3 clinical trial evaluating its microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Eric Soyer
Chief Financial Officer
Email: invest@maat-pharma.com
Phone: 04 28 29 14 00
MaaT Pharma
70 avenue Tony Garnier, 69007 Lyon